Novartis Management

Management criteria checks 2/4

Novartis' CEO is Vas Narasimhan, appointed in Feb 2018, has a tenure of 6.83 years. total yearly compensation is $15.78M, comprised of 13.7% salary and 86.3% bonuses, including company stock and options. directly owns 0.016% of the company’s shares, worth R$193.51M. The average tenure of the management team and the board of directors is 3.3 years and 8.8 years respectively.

Key information

Vas Narasimhan

Chief executive officer

US$15.8m

Total compensation

CEO salary percentage	13.7%
CEO tenure	6.8yrs
CEO ownership	0.02%
Management average tenure	3.3yrs
Board average tenure	8.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Vas Narasimhan's remuneration changed compared to Novartis's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2024	n/a	n/a	US$12b
Jun 30 2024	n/a	n/a	US$10b
Mar 31 2024	n/a	n/a	US$9b
Dec 31 2023	US$16m	US$2m	US$9b
Sep 30 2023	n/a	n/a	US$7b
Jun 30 2023	n/a	n/a	US$7b
Mar 31 2023	n/a	n/a	US$6b
Dec 31 2022	US$12m	US$2m	US$6b
Sep 30 2022	n/a	n/a	US$21b
Jun 30 2022	n/a	n/a	US$22b
Mar 31 2022	n/a	n/a	US$24b
Dec 31 2021	US$12m	US$2m	US$23b
Sep 30 2021	n/a	n/a	US$10b
Jun 30 2021	n/a	n/a	US$9b
Mar 31 2021	n/a	n/a	US$8b
Dec 31 2020	US$12m	US$2m	US$8b
Sep 30 2020	n/a	n/a	US$7b
Jun 30 2020	n/a	n/a	US$7b
Mar 31 2020	n/a	n/a	US$7b
Dec 31 2019	US$12m	US$2m	US$7b
Sep 30 2019	n/a	n/a	US$7b
Jun 30 2019	n/a	n/a	US$7b
Mar 31 2019	n/a	n/a	US$13b
Dec 31 2018	US$10m	US$2m	US$13b
Sep 30 2018	n/a	n/a	US$14b
Jun 30 2018	n/a	n/a	US$14b
Mar 31 2018	n/a	n/a	US$8b
Dec 31 2017	US$5m	US$864k	US$7b

Compensation vs Market: Vas's total compensation ($USD15.78M) is above average for companies of similar size in the BR market ($USD5.71M).

Compensation vs Earnings: Vas's compensation has increased by more than 20% in the past year.

CEO

Vas Narasimhan (48 yo)

6.8yrs

Tenure

US$15,778,038

Compensation

Dr. Vasant Narasimhan, also known as Vas, M.D., serves as Chief Executive Officer of Novartis AG at Novartis India Ltd. Dr. Narasimhan has been Chief Executive Officer of Novartis AG since February 1, 2018...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Vasant Narasimhan	Chief Executive Officer	6.8yrs	US$15.78m	0.016% R$ 193.5m
Harry Kirsch	Chief Financial Officer	11.6yrs	US$7.76m	0.019% R$ 223.8m
Victor Bulto	President of US	2.7yrs	US$6.13m	0.0017% R$ 20.0m
Patrick Horber	President of International	less than a year	US$7.95m	0.0014% R$ 16.3m
Steffen Lang	President of Operations	2.7yrs	US$4.17m	0.0077% R$ 90.5m
Paul Penepent	Head of Group Financial Reporting and Accounting	no data	no data	no data
Sloan Simpson	Global Head of Investor Relations	less than a year	no data	no data
Klaus Moosmayer	Chief Ethics	6yrs	US$2.67m	0.0019% R$ 21.9m
Karen Hale	Chief Legal Officer	3.6yrs	US$4.16m	0.0012% R$ 14.2m
Robert Kowalski	Chief People & Organization Officer	3.3yrs	US$3.45m	0.0011% R$ 12.6m
Etienne Jousseaume	Head of Market Access	no data	no data	no data
Linda Armstrong	Global Head of Respiratory Development	no data	no data	no data

3.3yrs

Average Tenure

56yo

Average Age

Experienced Management: N1VS34's management team is considered experienced (3.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Sidonie Golombowski-Daffner	Chairperson & President of Advanced Accelerator Applications	no data	no data	no data
Simon Moroney	Independent Vice Chairman of the Board	4.8yrs	US$546.92k	0.00030% R$ 3.5m
Daniel Vasella	Honorary Chairman	no data	US$3.34m	no data
Bridgette Heller	Independent Non-Executive Director	4.8yrs	US$511.25k	0.00031% R$ 3.7m
Joerg Reinhardt	Independent Non-Executive Chairman	11.3yrs	US$4.52m	0.033% R$ 387.3m
François van Houten	Independent Non-Executive Director	7.8yrs	US$469.25k	0.00086% R$ 10.2m
Ton Buechner	Independent Non-Executive Director	8.8yrs	US$504.92k	0.0011% R$ 13.6m
William Winters	Independent Non-Executive Director	11.9yrs	US$428.02k	0.0015% R$ 18.2m
Charles Sawyers	Independent Non-Executive Director	11.9yrs	US$428.02k	0.00087% R$ 10.3m
Patrice Bula	Lead Independent Director	5.8yrs	US$491.97k	0.00056% R$ 6.6m
Nancy Andrews	Independent Non-Executive Director	9.8yrs	US$428.02k	0.00053% R$ 6.3m
Elizabeth Doherty	Independent Non-Executive Director	8.8yrs	US$535.03k	0.00074% R$ 8.7m

8.8yrs

Average Tenure

65yo

Average Age

Experienced Board: N1VS34's board of directors are considered experienced (8.8 years average tenure).

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/22 15:43
End of Day Share Price	2024/12/20 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Novartis AG is covered by 68 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Kamla Singh	AlphaValue
John Eade	Argus Research Company
Fabrizio Spagna	Axia Financial Research

Novartis Management

Management criteria checks 2/4

Key information

Recent management updates

Novartis AG, Annual General Meeting, Mar 07, 2025

Recent updates

Novartis Inc. Announces Results from an Updated Analysis of the Pivotal Phase III Natalee Trial of Kisqali®? (ribociclib)

Novartis Announces Positive, Long-Term Results from the Pivotal Phase III ASC4FIRST Trial with Scemblix (asciminib)

Novartis Announces Positive Topline Results from APPULSE-PNH, a Phase IIIB Study Evaluating the Efficacy and Safety of Two-Daily Oral Monotherapy Fabhalta

Novartis Kisqali Receives European Commission Approval in A Broad Population of Patients with HR+/HER2- Early Breast Cancer at High Risk of Recurrence

Novartis AG (SWX:NOVN) acquired Kate Therapeutics, Inc. in a transaction valued at $1.1 billion.

Novartis' Scemblix® Receives Approval from US Food and Drug Administration

Novartis Raises Earnings Guidance for the Fiscal Year 2024

Novartis Receives Positive CHMP Opinion for Kisqali to Help Reduce Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

Novartis AG, Annual General Meeting, Mar 07, 2025

Alkem Labs Reportedly in Talks to Acquire Novartis India from Its Swiss Parent

Novartis Announces Positive Topline Results from Twice-Yearly Leqvio (Inclisiran) in the Phase III V-Mono Study

Siemens Healthineers Offers to Buy Novartis Molecular Imaging Business

Novartis Receives FDA Accelerated Approval for Fabhalta (iptacopan)

Novartis AG to Report Q4, 2024 Results on Jan 31, 2025

Novartis AG Presents Latest Phase III Fabhalta®? (iptacopan) Data in C3 Glomerulopathy (C3G)

Novartis AG (SWX:NOVN) entered into an agreement to acquire Mariana Oncology, Inc. from Atlas Venture L.P., Access Biotechnology, RA Capital Management, L.P., Deep Track Capital, LP, Forbion Capital Partners B.V. and others for $1.8 billion.

Novartis and Medicines for Malaria Venture Announce Positive Efficacy and Safety Data for A Novel Treatment for Babies

Novartis AG Revise Earnings Guidance for the Year 2024

Novartis' Intravenous Formulation of Cosentyx Impacting Prescriber Preferences in Psoriatic Arthritis Treatment, While Pending Launch of UCB’s Bimzelx Poised to Further Disrupt the Market

Novartis Presents Results from Pre-Specified Interim Analysis of the Phase III APPLAUSE-IgAN study of Fabhalta

Novartis Fabhalta Receives Positive CHMP Opinion as First Oral Monotherapy for Adult Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Novartis AG (SWX:NOVN) acquired IFM Due, Inc. from IFM Therapeutics, LLC for approximately $840 million.

Dr. Reddy's Laboratories Denies in Race to Acquire Novartis' Stake in Novartis India

Dr Reddy's Reportedly May Join Race to Acquire Novartis' India Arm

Novartis AG Announces FDA Approves Xolair® (Omalizumab) as First and Only Medicine for Children and Adults with One or More Food Allergies

Novartis Reportedly in Lead to Acquire MorphoSys

Novartis AG Provides Earnings Guidance for the Year 2024

Novartis AG to Report Q1, 2024 Results on Apr 23, 2024

Novartis AG Presents Data from the Phase III NETTER-2 Trial

Novartis Pursuit of Cytokinetics Reportedly Cools

Novartis Reportedly in Advanced Talks to Buy Cytokinetics

Novartis AG Announces Positive Results from the Primary Analysis of ASC4FIRST

Novartis AG (SWX:NOVN) acquired SanReno Therapeutics from Pivotal bioVenture Partners China, Versant Venture Management, LLC, Samsara BioCapital LLC, Frazier Healthcare Partners managed by Frazier Management, L.L.C. and Frazier Life Sciences Management, LP.

Novartis Investigational Iptacopan Phase III Study Demonstrates Clinically Meaningful and Statistically Significant Proteinuria Reduction in Patients with C3 Glomerulopathy (C3G)

Latest Novartis Kisqali(R) Natalee Analysis Reinforces 25% Reduction in Risk of Recurrence Across Broad Population of Patients with Early Breast Cancer

Novartis Receives FDA Approval for Fabhalta (iptacopan) Offering Superior Hemoglobin Improvement in the Absence of Transfusions as the First Oral Monotherapy for Adults with PNH

Novartis AG to Report Q4, 2023 Results on Jan 31, 2024

Novartis Announces New Positive Data from the Phase III REMIX-1 and REMIX-2 Studies Investigating Remibrutinib

Novartis Announces US Food and Drug Administration Approves Cosentyx® to Treat Moderate to Severe Hidradenitis Suppurativa in Adults

Novartis Announces Positive Topline Results from the Interim Analysis of the Ongoing Pivotal Phase III ALIGN Study

Novartis AG Announces Impairment Charges for the Third Quarter of 2023

Novartis AG Raises Earnings Guidance for the Fiscal Year 2023

Novartis Kisqali Natalee Analysis Confirms Consistent Reduction in Risk of Recurrence Across Key Sub Groups of Patients with Early Breast Cancer

FDA Approves Novartis Cosentyx® as First Intravenous (Iv) Formulation Interleukin-17A Antagonist for Rheumatic Diseases

Novartis to Present New Oncology Data at ESMO 2023 Demonstrating Practice-Changing Innovation in Advanced Prostate and Early Breast Cancer

Novartis AG completed the Spin-Off of Sandoz Group AG (SWX:SDZ).

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources